- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05377047
Radioterapia ablativa estereotáctica para el cáncer de mama oligometastásico (TAORMINA)
Tratamiento del cáncer de mama oligometastásico: un ensayo aleatorizado de fase 3 que compara la radioterapia ablativa estereotáctica y el tratamiento sistémico con el tratamiento sistémico solo como tratamiento de primera línea
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.
Patients with 1-5 metastases in 1-2 organs (confirmed by PET-CT) with any breast cancer subtype can be enrolled. All metastases must be available for SABR.
The primary aim is to investigate if the addition of SABR to the oligometastatic sites in addition to the standard first-line treatment can improve progression-free survival (PFS).
Secondary aims are to compare overall survival (OS), response rate and time to development of new lesions, acute and late toxicity. quality of life, time to start of chemotherapy (luminal patients).
Exploratory analyses:
Circulating tumour DNA as an early sign of disease progression. Immun panel for determination of the effect of SABR on patients´ immune response.
To investigate the survival for each BC subtype (Luminal, HER2+ and TNBC). To investigate survival in patients with de novo OMBC and recurrent OMBC respectively.
Stratifications are based on subtype (luminal, HER2-positive vs TNBC) and type of OMBC (de novo vs. recurrent) without formal sample size calculation for the stratification factor (exploratory analysis).
Patients with de novo metastatic OMBC that is planned for neoadjuvant treatment are recommended to complete treatment followed by standard surgery and radiotherapy or SABR towards the primary tumour lesion(s).
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Katarzyna Kulbacka-Ortiz, CTO
- Número de teléfono: +46721470685
- Correo electrónico: katarzyna.kulbacka-ortiz@vgregion.se
Copia de seguridad de contactos de estudio
- Nombre: Annika Baan
- Número de teléfono: +46700906097
- Correo electrónico: annika.baan@vgregion.se
Ubicaciones de estudio
-
-
-
Ljubljana, Eslovenia, 1000
- Reclutamiento
- Institute of Oncology Ljubljana
-
Contacto:
- Minka Macanovic
- Número de teléfono: +386 (0)1 58 79 550
- Correo electrónico: mmacanovic@onko-i.si
-
Contacto:
- Erika Primc
- Correo electrónico: eprimc@onko-i.si
-
Investigador principal:
- Ivica Ratoša, MD
-
-
-
-
-
Cork, Irlanda, T12 DC4A
- Reclutamiento
- Cork University Hospital
-
Contacto:
- Ella O'Sullivan, MD
- Número de teléfono: +353 (0) 21 4922000
- Correo electrónico: ella.osullivan@hse.ie
-
Investigador principal:
- Aisling Barry, Prof.
-
Cork, Irlanda, T12 DV56
- Reclutamiento
- Bon Secours Cork In Partnership with UPMC Hillman Cancer Centre
-
Contacto:
- Karen Molan, MD
- Número de teléfono: +353 (0)21-486 1100
- Correo electrónico: molank@upmc.ie
-
Investigador principal:
- Kathy Rock, MD
-
Dublin, Irlanda
- Reclutamiento
- St Luke's Radiation Oncology Network (SLRON) at St Luke's Hospital Dublin, St James Hospital Dublin and Beaumont Hospital Dublin
-
Contacto:
- Vitor Oliviera
- Número de teléfono: +353 (0) -1-420 6900
- Correo electrónico: Vitor.Oliveira@slh.ie
-
Investigador principal:
- Frances Duane, Prof.
-
Galway, Irlanda, H91 YR71
- Reclutamiento
- University Hospital Galway (UHG)
-
Contacto:
- Laura Nally
- Número de teléfono: +353 91 54 2785
- Correo electrónico: laura.nally@hse.ie
-
Investigador principal:
- Ronan McDermott, MD
-
-
-
-
-
Tel Aviv, Israel, 5265601
- Reclutamiento
- Sheba Medical Center Institute of Oncology
-
Contacto:
- Aliza Ackerstein
- Número de teléfono: +972-3-5302542
- Correo electrónico: aliza.ackerstein@sheba.health.gov.il
-
Contacto:
- Chen Gross
- Correo electrónico: Chen.Gross@sheba.health.gov.il
-
Investigador principal:
- Einav Nili Gal-Yam, MD
-
-
-
-
-
Florence, Italia, 3 50134
- Reclutamiento
- Azienda Ospedaliero - Universitaria Careggi
-
Contacto:
- Michela Carracino
- Número de teléfono: +390552751828
- Correo electrónico: carracinom@aou-careggi.toscana.it
-
Investigador principal:
- Icro Meattini, Prof.
-
Milan, Italia
- Reclutamiento
- Humanitas Cancer Centre
-
Contacto:
- Marta Scorsetti, MD, PhD
- Número de teléfono: +39 02 8224 8524
- Correo electrónico: marta.scorsetti@hunimed.eu
-
Investigador principal:
- Marta Scorsetti, Prof.
-
Milan, Italia
- Reclutamiento
- Istituto Nationale Tumori (INT)
-
Contacto:
- Maria Carmen De Santis, MD
- Número de teléfono: +39-0223903280
- Correo electrónico: mariacarmen.desantis@istitutotumori.mi.it
-
Investigador principal:
- Maria Carmen De Santis, Prof.
-
-
-
-
-
Bergen, Noruega, 5021
- Reclutamiento
- Haukeland University Hospital
-
Contacto:
- Vidhi Shukla, MD
- Número de teléfono: +47 55 97 50 00
- Correo electrónico: vidi.shukla@helse-bergen.no
-
Investigador principal:
- Vidhi Shukla, MD
-
Oslo, Noruega, 0424
- Reclutamiento
- Oslo University Hospital, Radiumhospitalet
-
Contacto:
- Veronica Feilum
- Número de teléfono: +47-942244
- Correo electrónico: uxfeve@ous-hf.no
-
Contacto:
- Maria Elena Rodriguez Aguillar
- Correo electrónico: maerod@ous-hf.no
-
Investigador principal:
- Vidar Gordon Flote, MD, PhD
-
Tromsø, Noruega, 9019
- Reclutamiento
- Universitetssykehuset Nord-Norge
-
Contacto:
- Kristin Iren Jensen
- Número de teléfono: + 47 77 66 92 12
- Correo electrónico: Kristin.Iren.Jensen@unn.no
-
Contacto:
- Maria Therese Danielsen
- Correo electrónico: maria.theres.danielsen@unn.no
-
Investigador principal:
- Hanna Stromholt Bremnes, MD
-
Trondheim, Noruega, 7006
- Reclutamiento
- St. Olavs Hospital
-
Contacto:
- Kjerstin Olaussen
- Número de teléfono: +47-72825782
- Correo electrónico: Kjerstin.Olaussen@stolav.no
-
Contacto:
- Britt Torun Fjær Nydal
- Correo electrónico: Britt.Torunn.Fjer.Nydal@stolav.no
-
Investigador principal:
- Solveig Hoff
-
-
-
-
Region Jönköpings Län
-
Jönköping, Region Jönköpings Län, Suecia, 551 85
- Reclutamiento
- Ryhov County Hospital
-
Investigador principal:
- Maria Ekholm, MD, PhD
-
Contacto:
- Therese Karlsson, Study nurse
- Número de teléfono: +46 10-242 59 62
- Correo electrónico: therese.i.karlsson@rjl.se
-
-
Region Skåne
-
Malmö, Region Skåne, Suecia
- Reclutamiento
- Skånes University Hospital
-
Contacto:
- Charlotta Wollheim, Study nurse
- Número de teléfono: +46 40 337461
- Correo electrónico: charlotta.wollheim@skane.se
-
Investigador principal:
- Muhammad Kadum, MD
-
-
Region Stockholm
-
Stockholm, Region Stockholm, Suecia, 17176
- Reclutamiento
- Karolinska University Hospital
-
Contacto:
- Karin Hedgren, Study nurse
- Número de teléfono: +46-8-123 71746
- Correo electrónico: karin.hedgren@regionstockholm.se
-
Investigador principal:
- Caroline Boman, MD
-
-
Region Västerbotten
-
Umeå, Region Västerbotten, Suecia, 901 85
- Reclutamiento
- Norrlands University Hospital
-
Contacto:
- Dmitry Domkin, Study nurse
- Número de teléfono: +46 90-785 35 95
- Correo electrónico: dmitry.domkin@regionvasterbotten.se
-
Contacto:
- Jeanette Johansson, Study nurse
- Número de teléfono: +46-90-785 06 89
- Correo electrónico: jeanette.johansson@regionvasterbotten.se
-
Investigador principal:
- Kristina Weibring, MD, PhD
-
-
Region Örebro Län
-
Örebro, Region Örebro Län, Suecia, SE-701 85
- Reclutamiento
- Örebro University Hospital
-
Contacto:
- Emma Nordh, Study nurse
- Número de teléfono: +46 19 602 27 19
- Correo electrónico: emma.nordh@regionorebrolan.se
-
Contacto:
- Jenny Larsson, Study nurse
- Número de teléfono: +46-31-3426791
- Correo electrónico: jenny.larsson4@regionorebrolan.se
-
Investigador principal:
- Eva Tegnelius, MD
-
-
Västra Götalandsregionen
-
Gothenburg, Västra Götalandsregionen, Suecia, 41345
- Reclutamiento
- Sahlgrenska University Hospital
-
Contacto:
- Katarzyna Kulbacka, Head CTO
- Correo electrónico: katarzyna.kulbacka-ortiz@vgregion.se
-
Contacto:
- Mitra Sharifi Jahanfard, Study nurse
- Número de teléfono: +46-31-3426791
- Correo electrónico: mitra.sharifi-jahanfard@vgregion.se
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Histologically or cytological confirmed recurrent OMBC.
-
Age ≥18 years old.
-
OMBC defined as 1-5 metastases in a maximum of two organs confirmed by PET-CT.
-
Patients already on 1st line systemic treatment can be enrolled if repeated tumour evaluations show stable disease.
-
Patients with de novo stage IV OMBC must have a controlled primary tumour regardless of primary surgery or primary systemic treatment.
-
Patients with local recurrence and OMBC must have a controlled local recurrence.
-
ECOG/WHO 0-2.
-
Life expectancy > 6 months.
-
Known ER, PgR and HER2 status of either primary tumour or metastasis (preferred).
-
Symptomatic bone metastases are allowed if ablative therapy can be delivered.
-
Adequate organ function for the planned treatment according to local guide-lines.
-
For patients with liver metastasis:
-
No cirrhosis or hepatitis
-
Hepatic function:
- Total bilirubin level < 3.0 x institutional ULN
- ALT, AST, GGT, and alkaline phosphatase levels < 3.0 x institutional ULN
- Albumin > 2.5 mg/dL
-
Metastasis not adjutant to stomach or small bowel.
-
-
For patients with abdominal metastases: adequate renal function with a calculated creatinine clearance of > 60mL/min.
-
Toxicities from previous adjuvant therapies (excluding alopecia) must have recovered to grade 1 (defined by CTCAE 5.0). Stable grade 2 peripheral neuropathy are considered individually by the investigator.
-
Negative pregnancy test within 14 days prior to start of treatment*.
-
If childbearing potential, willing to use an effective form of contraception*.
-
No other malignancy during the last 5 years except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix.
-
Signed informed consent and willingness to follow the trial procedures.
Exclusion Criteria:
- > 1 line of systemic treatment for OMBC due to previous progressing disease (previous treatment of isolated local recurrences with a 2nd adjuvant treatment not included). Change due to toxicity allowed.
- Oligometastases in brain.
- Malignant pleural effusion or ascites.
- Metastasis growth that involves > 3 vertebra and adjacent spinal cord, spine instability or neurological deficit resulting from compression, 25% spinal canal compromise or progressive neurological deficit.
- Unable to undergo imaging by either CT scan or MRI.
- Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment or affect patient compliance.
- Pregnancy or breast-feeding.
- Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Experimental SABR arm
Standard first line systemic therapy + SABR. |
Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions. |
|
Sin intervención: Control systemic therapy arm
Standard first line systemic therapy. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-free survival (PFS)
Periodo de tiempo: 3 years after the last patient inclusion
|
Time from the date of randomisation to the date of disease-progression at any site or death from any cause. |
3 years after the last patient inclusion
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall survival (OS)
Periodo de tiempo: 3 years after the last patient inclusion
|
Time from the date of randomisation to the date of death from any cause. |
3 years after the last patient inclusion
|
|
Local Control Rate (LCR)
Periodo de tiempo: 3 years after the last patient inclusion
|
Time from the date of randomisation to the date of progress in previously treated metastases |
3 years after the last patient inclusion
|
|
Safety analysis - acute toxicity
Periodo de tiempo: From the first dose of SABR to 3 months after the last dose of SABR
|
Reported according to CTCAE v.5.0 |
From the first dose of SABR to 3 months after the last dose of SABR
|
|
Safety analysis - late toxicity
Periodo de tiempo: From the first dose of SABR to 3 years after the last dose of SABR
|
Reported according to CTCAE v.5.0 |
From the first dose of SABR to 3 years after the last dose of SABR
|
|
Health-related quality of life Cancer-30
Periodo de tiempo: At base-line and after 3, 6, 9, 12, 18, 24 and 36 months after registration.
|
European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaires Cancer-30 (EORTC-QLQ C30) |
At base-line and after 3, 6, 9, 12, 18, 24 and 36 months after registration.
|
|
Health-related quality of life Breast-23
Periodo de tiempo: At base-line and after 3, 6, 9, 12, 18, 24 and 36 months after registration.
|
European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Breast-23 (EORTC-QLQ B23) |
At base-line and after 3, 6, 9, 12, 18, 24 and 36 months after registration.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Barbro K Linderholm, MD, PhD, Sahlgrenska University Hospital, Gothenburg
Publicaciones y enlaces útiles
Publicaciones Generales
- Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):878-86. doi: 10.1016/j.ijrobp.2011.08.036. Epub 2011 Dec 13.
- Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009 Jun;115(3):601-8. doi: 10.1007/s10549-008-0157-4. Epub 2008 Aug 22.
- Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, Alongi F, Del Conte A, Militello L, Muraro E, Martorelli D, Spazzapan S, Berretta M. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiother Oncol. 2018 Jan;126(1):177-180. doi: 10.1016/j.radonc.2017.08.032. Epub 2017 Sep 21.
- Milano MT, Katz AW, Zhang H, Huggins CF, Aujla KS, Okunieff P. Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade. Radiother Oncol. 2019 Feb;131:45-51. doi: 10.1016/j.radonc.2018.11.022. Epub 2018 Dec 28.
- Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman GS, Laba J, Qu XM, Warner A, Senan S. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020 Sep 1;38(25):2830-2838. doi: 10.1200/JCO.20.00818. Epub 2020 Jun 2.
- Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, Coker B, Patrick H, Powell H, Berry L, Webster G, Ostler P, Dickinson PD, Hatton MQ, Henry A, Keevil S, Hawkins MA, Slevin N, van As N. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021 Jan;22(1):98-106. doi: 10.1016/S1470-2045(20)30537-4.
- Scorsetti M, Franceschini D, De Rose F, Comito T, Villa E, Iftode C, Navarria P, D'Agostino GR, Masci G, Torrisi R, Testori A, Tinterri C, Santoro A. Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. Breast. 2016 Apr;26:11-7. doi: 10.1016/j.breast.2015.12.002. Epub 2016 Jan 3.
- David S, Tan J, Savas P, Bressel M, Kelly D, Foroudi F, Loi S, Siva S. Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial. Breast. 2020 Feb;49:55-62. doi: 10.1016/j.breast.2019.10.016. Epub 2019 Nov 6.
- Li MP, Kelly D, Tan J, Siva S, Kron T, David S. Single-fraction stereotactic ablative body radiotherapy for sternal metastases in oligometastatic breast cancer: Technique and single institution experience. J Med Imaging Radiat Oncol. 2020 Aug;64(4):580-585. doi: 10.1111/1754-9485.13075. Epub 2020 Jun 25.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SABO 21-01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .